Eculizumab biosimilar, a humanized monoclonal antibody that works by selectively inhibiting activation of specific proteins in the complement system (C5a and C5b), which play a role in the pathophysiology of multiple rare diseases. Indications include paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, euromyelitis optica spectrum disorder.

Eculizumab is already approved in Russia, the application for registration on the international markets is being prepared.